
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
Highlights from the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, which took place virtually on February 26-March 1.






